End of a long and very interesting first day of the #AYA cancer preceptorship. ESMO - Eur. Oncology It felt like a crash course in oncology.

Already 100 attendees registered for FORTRESS 2024 in Leuven - only a few places left, as we are limiting the number of participants at the workshop! Check our webpage for all relevant details: kuleuven.be/fortress

Interested in the molecular epidemiology of novel and potentially actionable drug targets in synovial sarcoma? See Lore De Cock’s tissue microarray-based poster at CTOS today. This new platform is so useful for target identification.

Wonderful and very educational masterclass. Would highly recommend this to everyone interested in sarcoma! ANASTASIOS KYRIAZOGLOU Hellenic Group of Sarcomas and rare tumors

Interesting data for IDRX-42, new KIT inhibitor, in #GIST, just presented at #ASCO24 by Patrick Schöffski 🚨phase I, multiple dose levels, heterogenous population but... 📈high rate of responses across different dose levels, especially in 2nd line

🔬 #ASCO2024 Insight: Prof Mariana Brandao presents findings from the KEYNOTE-671 trial on quality of life in NSCLC patients. Quality of life returns to baseline after one year, with no significant differences in toxicity.